The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib
Abstract
Purpose: Gastrointestinal stromal tumors (GISTs) commonly harbor oncogenic mutations of the KIT tyrosine kinase, which is a target for the kinase inhibitor imatinib. A subset of GISTs, however, contains mutations in the homologous kinase platelet derived growth factor receptor alpha (PDGFRA), and the most common of these mutations is resistant to imatinib in vitro. Little is known of the other types of PDGFRA mutations that occur in GISTs. Materials and Methods: We determined the KIT and PDGFRA mutation status of 1,105 unique GISTs using a combination of denaturing high-performance liquid chromatography and direct sequencing. Results: There were 80 tumors (7.2%) with a PDGFRA mutation: 66 in exon 18, 11 in exon 12, and three in exon 14. Transient expression of representative PDGFRA isoforms in CHO cells revealed imatinib sensitivity of exon 12 mutations (SPDHE566-571R and insertion ER561-562) and an exon 14 substitution (N659K). However, most isoforms with a substitution involving codon D842 in exon 18 (D842V, RD841-842KI, DI842-843IM) were resistant to the drug, with the exception of D842Y. Interestingly, other mutations in exon 18 (D846Y, N848K, Y849K and HDSN845-848P) were all imatinib sensitive. Proliferation studies with BA/F3 cell lines stably expressing selected PDGFRA mutant isoforms supported these findings. Conclusion: Including our cases, there are 289 reported PDGFRA-mutant GISTs, of which 181 (62.6%) had the imatinib-resistant substitution D842V. However, our findings suggest that more than one third of GISTs with PDGFRA mutations may respond to imatinib and that mutation screening may be helpful in the management of these tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citationPDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Duensing, A., McGreevey, L., Chen, C.-J., Joseph, N., Singer, S., Griffith, D. J., Haley, A., Town, A., et al. (2003) · Science · doi:10.1126/science.1079666 · Cited by 2,301
Self-citationKinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., von Mehren, M., Joensuu, H., McGreevey, L. S., Chen, C.-J., Van den Abbeele, A. D., Druker, B. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.190 · Cited by 2,299
Self-citationCools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
van Oosterom, A. T., Judson, I., Verweij, J., Stroobants, S., di Paola, E. D., Dimitrijevic, S., Martens, M., Webb, A., Sciot, R., Van Glabbeke, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06535-7 · Cited by 1,264
Biology of Gastrointestinal Stromal Tumors
Corless, C. L., Fletcher, J. A., & Heinrich, M. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.140 · Cited by 1,224
Self-citationHirota, S., Ohashi, A., Nishida, T., Isozaki, K., Kinoshita, K., Shinomura, Y., & Kitamura, Y. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01046-1 · Cited by 666
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review
Miettinen, M., Majidi, M., & Lasota, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80602-5 · Cited by 545
Debiec-Rychter, M., Cools, J., Dumez, H., Sciot, R., Stul, M., Mentens, N., Vranckx, H., Wasag, B., Prenen, H., Roesel, J., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.020 · Cited by 494
KIT-Negative Gastrointestinal Stromal Tumors: Proof of Concept and Therapeutic Implications
Medeiros, F., Corless, C. L., Duensing, A., Hornick, J. L., Oliveira, A. M., Heinrich, M. C., Fletcher, J. A., & Fletcher, C. D. M. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00007 · Cited by 486
Self-citationHeinrich, M. C., Rubin, B. P., Longley, B. J., & Fletcher, J. A. (2002) · Human Pathology · doi:10.1053/hupa.2002.124124 · Cited by 455
Self-citationMa, Y., Zeng, S., Metcalfe, D. D., Akin, C., Dimitrijevic, S., Butterfield, J. H., McMahon, G., & Longley, B. J. (2002) · Blood · doi:10.1182/blood.v99.5.1741 · Cited by 449
Corless, C. L., McGreevey, L., Haley, A., Town, A., & Heinrich, M. C. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61103-0 · Cited by 444
Self-citationDebiec-Rychter, M., Dumez, H., Judson, I., Wasag, B., Verweij, J., Brown, M., Dimitrijevic, S., Sciot, R., Stul, M., Vranck, H., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.025 · Cited by 444
Antonescu, C. R., Sommer, G., Sarran, L., Tschernyavsky, S. J., Riedel, E., Woodruff, J. M., Robson, M. E., Maki, R. G., Brennan, M. F., Ladanyi, M., et al. (2003) · PubMed · Cited by 359
Strategies to overcome resistance to targeted protein kinase inhibitors
Daub, H., Specht, K., & Ullrich, A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1579 · Cited by 334
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
KIT Mutations Are Common in Testicular Seminomas
Kemmer, K., Corless, C. L., Fletcher, J. A., McGreevey, L., Haley, A., Griffith, D., Cummings, O. W., Wait, C., Town, A., & Heinrich, M. C. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63120-3 · Cited by 322
Self-citationLasota, J., Dansonka-Mieszkowska, A., Sobin, L. H., & Miettinen, M. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700122 · Cited by 317
PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor
Chompret, A., Kannengiesser, C., Barrois, M., Terrier, P., Dahan, P., Tursz, T., Lenoir, G. M., & Bressac-De Paillerets, B. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.079 · Cited by 237
Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity
Debiec‐Rychter, M., Wasag, B., Stul, M., De Wever, I., Van Oosterom, A., Hagemeijer, A., & Sciot, R. (2004) · The Journal of Pathology · doi:10.1002/path.1546 · Cited by 213
Sihto, H., Sarlomo-Rikala, M., Tynninen, O., Tanner, M., Andersson, L. C., Franssila, K., Nupponen, N. N., & Joensuu, H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.093 · Cited by 196
Tse, K.-F., Mukherjee, G., & Small, D. (2000) · Leukemia · doi:10.1038/sj.leu.2401905 · Cited by 195
Zermati, Y., De Sepulveda, P., Féger, F., Létard, S., Kersual, J., Castéran, N., Gorochov, G., Dy, M., Ribadeau Dumas, A., Dorgham, K., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206120 · Cited by 191
Subramanian, S., West, R. B., Corless, C. L., Ou, W., Rubin, B. P., Chu, K., Leung, S. Y., Yuen, S. T., Zhu, S., Hernandez‐Boussard, T., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208056 · Cited by 149
Self-citationSynergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells
Yee, K. W. H., Schittenhelm, M. M., O'Farrell, A. M., Town, A., McGreevey, L. S., Bainbridge, T., Cherrington, J. M., & Heinrich, M. C. (2004) · Blood · doi:10.1182/blood-2003-10-3381 · Cited by 130
Self-citationKang, H. J., Nam, S. W., Kim, H., Rhee, H., Kim, N.-G., Kim, H., Hyung, W. J., Noh, S. H., Kim, J.-H., Yun, C., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208358 · Cited by 100
Sakurai, S., Hasegawa, T., Sakuma, Y., Takazawa, Y., Motegi, A., Nakajima, T., Saito, K., Fukayama, M., & Shimoda, T. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.008 · Cited by 99
Beghini, A., Magnani, I., Ripamonti, C. B., & Larizza, L. (2002) · The Hematology Journal · doi:10.1038/sj.thj.6200168 · Cited by 69
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970
Corbin, A. S., Griswold, I. J., Rosée, P. G. L., Yee, K. W. H., Heinrich, M. C., Reimer, C., Druker, B. J., & Deininger, M. W. (2004) · Blood · doi:10.1182/blood-2004-06-2189 · Cited by 68
Self-citationStructural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
Mol, C. D., Fabbro, D., & Hosfield, D. J. (2004) · PubMed · Cited by 67
Corbin, A. S., Demehri, S., Griswold, I. J., Wang, Y., Metcalf, C. A., Sundaramoorthi, R., Shakespeare, W. C., Snodgrass, J. T., Wardwell, S., Dalgarno, D. C., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4771 · Cited by 60
Self-citationSchittenhelm, M. M., Shiraga, S., Lee, F. Y., & Heinrich, M. C. (2004) · Blood · doi:10.1182/blood.v104.11.2424.2424 · Cited by 7
Self-citation
Cited by
Miettinen, M., & Lasota, J. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-1466-gstrom · Cited by 1,459
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., Pisters, P. W. T., Raut, C. P., Riedel, R. F., Schuetze, S., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0116 · Cited by 1,219
Gastrointestinal stromal tumour
Rubin, B. P., Heinrich, M. C., & Corless, C. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60780-6 · Cited by 1,036
Self-citationGastrointestinal stromal tumours: origin and molecular oncology
Corless, C. L., Barnett, C. M., & Heinrich, M. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3143 · Cited by 891
Self-citationMolecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Self-citation
Metadata
- Authors
- Corless, C. L., Schroeder, A., Griffith, D., Town, A., McGreevey, L., Harrell, P., Shiraga, S., Bainbridge, T., Morich, J., & Heinrich, M. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-10
- Volume
- 23
- Issue
- 23
- Pages
- 5357-5364
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102769930
- Cited by
- 849
- References
- 33
- FWCI
- 30.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.